Laboratoire CERBA Enters into Licensing Agreement with IntegraGen for the Commercialization of miR-31-3p Tumor Expression Tes...
March 08 2017 - 2:00AM
Business Wire
Regulatory News:
IntegraGen SA (Paris:ALINT), a company specializing in
the decoding of the human genome and performing interpretable
genomic tests for academic and private laboratories and a developer
of diagnostic tools in oncology, and Laboratoire CERBA, the
European leader in specialized clinical pathology, serving more
than 50 countries in Europe, Africa and Asia, announced today the
signing of a licensing agreement allowing Laboratoire CERBA to
develop and provide to prescribing clinicians a test based on
IntegraGen’s proprietary miR-31-3p biomarker. Laboratoire CERBA
will develop this test to complement its existing portfolio and
further enable physicians to proactively identify metastatic
colorectal cancer patients who will have increased benefit from
treatment with anti-EGFR therapy. Financial details and terms
of the agreement were not disclosed.
“Laboratoire CERBA has a longstanding history of providing
innovative & clinically relevant tests to clinicians and
patients, and it is a natural expansion of our testing portfolio to
include miR-31-3p to our portfolio of tests. With this licensing
agreement we remain at the forefront of precision medicine and are
able to provide oncologists genomic information that will allow
them to choose the optimal therapy for patients with metastatic
colorectal cancer, a disease that affects more than 170,000
patients in the EU,” declared Sylvie Cado, CEO of Laboratoire
CERBA. “We look forward to making this test available for
clinicians in the first half of 2017 once we have completed the
validation steps in our laboratory.”
“This new partnership with Laboratoire CERBA is a significant
achievement for IntegraGen since it is a major step for the
company’s diagnostics activities,” added Bernard Courtieu,
IntegraGen’s CEO. “With the launch of our first proprietary test in
Europe, it also represents the culmination of more than five years
of research and development efforts, from the early stages of
biomarker discovery to the availability of a miR-31-3p expression
test for oncologists and patients. IntegraGen today delivers a big
step in the field of personalized medicine since this test
represents a major improvement for treating patients with
metastatic colorectal cancer.”
About IntegraGen
IntegraGen is a company specializing in deciphering the human
genome and producing relevant and easily interpretable data for
academic and private laboratories. IntegraGen’s oncology efforts
provide researchers and clinicians with sophisticated tools for
analysis and therapeutic individualization of treatment approaches
allowing them to tailor therapy to the genetic profiles of
patients. As of December 31, 2016, IntegraGen had 38 employees and
had generated revenue of €6.0 million in 2016. Based in Evry
Genopole, IntegraGen also has an U.S. office in Cambridge,
Massachusetts. IntegraGen is listed on Alternext of Euronext Paris
(ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).
www.integragen.com
About Laboratoire CERBA
Created in 1967 and accredited in compliance with the NF ISO
15189 standard since 1999, Laboratoire CERBA is the European leader
in specialized clinical pathology. Integrating more than 40 medical
specialties and employing over 600 highly qualified staff on a
single site located to the north-west of Paris, on average
Laboratoire CERBA handles some 40,000 dossiers daily.
With a state-of-the-art technological platform, it is able to
offer private and hospital laboratories in over 50 countries a wide
range of specialized clinical pathology tests in fields such as
molecular biology, oncology, allergology, toxicology, hormonology,
and infectious and metabolic diseases together with diagnostic
analyses for genetic diseases in cytogenetics and molecular
genomics.
Laboratoire CERBA ceaselessly works to develop its technological
and human potential and has launched numerous collaborative
projects with both public and private establishments to ensure it
always remains on the leading-edge of innovation. Since 1998,
Laboratoire CERBA's pathologists have contributed to over 500
scientific publications.
It is also a founder member of the CERBA HEALTHCARE group, an
international clinical pathology group, working in three
complementary sectors:
- routine clinical pathology mainly in
France, Belgium and Luxembourg with over 300 laboratories, 150
sample collection centers and 50 technical platforms;
- specialized clinical pathology with the
CERBA platform;
- clinical pathology for trial trials,
essential to the pharmaceutical and biotechnology industry for the
development of new molecules, through its subsidiary BARC today
present on five continents.
Recently the Group has diversified into the veterinary clinical
pathology sector with the creation of a dedicated unit, CERBA
VET.
It now employs nearly 4,300 staff, including 400
pathologists.
www.lab-cerba.com
www.cerbahealthcare.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170307006617/en/
IntegraGenBernard COURTIEU / Laurence RIOT
LAMOTTEPresident and CEO / Chief Financial
Officercontact@integragen.comTel: +33 (0)1 60 91 09
00orNewCapInvestors relationsEmmanuel HUYNHLouis-Victor
DELOUVRIERintegragen@newcap.euTel: +33 (0)1 44 71 98
53orLaboratoire CERBAPascale LAURENTDirector of
Communication and Marketingpascale.laurent@cerbahealthcare.com
Integragen (EU:ALINT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Integragen (EU:ALINT)
Historical Stock Chart
From Jul 2023 to Jul 2024